<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>BREAKING ADVANCES</td>
<td>Highlights from Recent Cancer Literature</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>REVIEWS</td>
<td>Long Intergenic Noncoding RNAs: New Links in Cancer Progression</td>
<td>Miao-Chih Tsai, Robert C. Spitale, and Howard Y. Chang</td>
</tr>
<tr>
<td>8</td>
<td>REVIEWS</td>
<td>Fetal Cell Microchimerism and Cancer: A Nexus of Reproduction, Immunology, and Tumor Biology</td>
<td>Lisa R. Kallenbach, Kirby L. Johnson, and Diana W. Bianchi</td>
</tr>
<tr>
<td>13</td>
<td>PRIORITY REPORT</td>
<td>Lactate Dehydrogenase B Is Critical for Hyperactive mTOR-Mediated Tumorigenesis</td>
<td>Xiaojun Zha, Fang Wang, Ying Wang, Shaozong He, Yanling Jing, Xuexin Wu, and Hongbing Zhang</td>
</tr>
<tr>
<td>19</td>
<td>CLINICAL STUDIES</td>
<td>Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of &quot;Rebound&quot; Revascularization as Mode of Escape</td>
<td>Emmanuelle di Tomaso, Matija Snuderl, Walid S. Kamoun, Dan G. Duda, Pavan K. Auluck, Ladan Fazlollahi, Ovidiu C. Andronesi, Matthew P. Frosch, Patrick Y. Wen, Scott R. Plotkin, E. Tessa Hedley-Whyte, A. Gregory Sorensen, Tracy T. Batchelor, and Rakesh J. Jain</td>
</tr>
<tr>
<td>29</td>
<td>INTEGRATED SYSTEMS AND TECHNOLOGIES</td>
<td>Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing</td>
<td>Zhi Jiang Zang, Choon Kiat Ong, Joanna Cutcutache, Willie Yu, Shen Li Zhang, Dachuan Huang, Lian Dee Lee, Karl Dykema, Anna Gan, Jiong Tao, Siyu Lim, Yujing Liu, P. Andrew Futreal, Heike Grabesch, Kyle A. Furge, Liang Kee Goh, Steve Rozen, Bin Tean Teh, and Patrick Tan</td>
</tr>
<tr>
<td>40</td>
<td>MICROENVIRONMENT AND IMMUNOLOGY</td>
<td>Endothelial Cell-Specific Deletion of Transcription Factor FoxM1 Increases Urethane-Induced Lung Carcinogenesis</td>
<td>David Balli, Yufang Zhang, Jonathan Snyder, Vladimir V. Kalinichenko, and Tanya V. Kalin</td>
</tr>
<tr>
<td>51</td>
<td>MICROENVIRONMENT AND IMMUNOLOGY</td>
<td>Tamoxifen, Flaxseed, and the Lignan Enterolactone Increase Stroma- and Cancer Cell-Derived IL-1Ra and Decrease Tumor Angiogenesis in Estrogen-Dependent Breast Cancer</td>
<td>Gabriel Lindahl, Niina Saarinen, Annelie Abrahamsson, and Charlotta Dabrosin</td>
</tr>
<tr>
<td>61</td>
<td>MICROENVIRONMENT AND IMMUNOLOGY</td>
<td>In vivo Antitumor Activity of a Recombinant IL-7/HGFβ Hybrid Cytokine in Mice</td>
<td>Laijun Lai, Jingjun Jin, and Irving Goldscheider</td>
</tr>
</tbody>
</table>
MOLECULAR AND CELLULAR PATHOBIOLOGY

68 BRCA2 and Nucleophosmin Coregulate Centrosome Amplification and Form a Complex with the Rho Effector Kinase ROCK2
Hui-Feng Wang, Katsuya Takenaka, Akira Nakanishi, and Yoshio Miki

Précis: Findings suggest that interactions between BRCA2 and NPM mediate suppression of hereditary breast and ovarian cancer.

78 Identification of New MicroRNAs in Paired Normal and Tumor Breast Tissue Suggests a Dual Role for the ERBB2/Her2 Gene
Helena Persson, Anders Kvist, Natalia Rego, Johan Staaf, Johan Vallon-Christersson, Lena Luts, Niklas Loman, Goran Jonsson, Hugo Naya, Mattias Hoglund, Ake Borg, and Carlos Rovira

Précis: Characterization of known and new microRNAs leads to the discovery of a new gene within the human ERBB2 oncogene.

87 Molecular Pathobiology of Human Cervical High-Grade Lesions: Paracrine STAT3 Activation in Tumor-Instructed Myeloid Cells Drives Local MMP-9 Expression
Nadine Schroer, Jennifer Phane, Barbara Walch, Claudia Wickenhauser, and Sigrun Smola

Précis: Findings define a molecular cascade that mechanistically rationalizes the design of new adjuvant therapies to treat cervical precancerous lesions and prevent their malignant progression.

98 Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy
Tommy Martinsson, Therese Eriksson, Jonas Abrahamsson, Helena Caren, Magnus Hansson, Per Kogner, Sattu Kamaraj, Christina Schönherr, Joel Weinmar, Kristina Rauth, Ruth H. Palmer, and Bengt Hallberg

Précis: Mutation of a critical kinase in neuroblastoma progression may be missed in the initial tumor biopsy, requiring testing later at progression.

Dose-Dependent Effects of Focal Fractionated Irradiation on Secondary Malignant Neoplasms in Afl Mutant Mice
Jean L. Nakamura, Connie Phong, Emile Pinarbasi, Scott C. Kogan, Scott Vandenberg, Andrew E. Horvai, Bruce A. Faddegon, Dorothea Fiedler, Kevan Shokat, Benjamin T. Houseman, Richard Chao, Russell O. Pieper, and Kevin Shannon

Précis: Findings offer the first validated mouse model to study secondary malignancies, an increasingly common complication of cancer therapy in survivors that has yet to be systematically analyzed.

PREVENTION AND EPIDEMIOLOGY

116 Risk of Infection-Related Cancers after the Loss of a Child: A Follow-up Study in Sweden
Fang Fang, Katja Fall, Pär Sparén, Hans-Olov Adami, Heiddis B. Valdimarsdóttir, Mats Lambe, and Unnur Valdimarsdóttir

Précis: Loss of a child associates with a higher risk of several cancers, chiefly ones that are associated with HPV infections.

123 A Randomized Trial of Dietary Intervention for Breast Cancer Prevention
Lisa J. Martin, Qing Li, Olga Melnichouk, Cary Greenberg, Salomon Minkin, Greg Hislop, and Norman F. Boyd

Précis: A sustained reduction in dietary fat intake did not reduce risk of breast cancer in women with extensive mammographic density.

THERAPEUTICS, TARGETS, AND CHEMICAL BIOLOGY

134 Carminomycin I Is an Apoptosis Inducer That Targets the Golgi Complex in Clear Cell Renal Carcinoma Cells
Girma M. Woldemichael, Thomas J. Turbyville, W. Marston Linehan, and James B. McMahon

Précis: Use of a natural products-based small molecule screening approach reveals a novel targeting strategy to attack clear cell renal cell carcinoma.
VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment
Wouter B. Nagengast, Marjolijn N. Lub-de Hooge, Sjoukje F. Osting, Wilfred F.A. den Dunnen, Frank-Jan Warners, Adrienne H. Brouwers, Johan R. de Jong, Patricia M. Price, Harry Hollema, Geke A.P. Hospers, Philip H. Elsinga, Jan Willem Hesseling, Jouk A. Gietema, and Elisabeth G.E. de Vries

Précis: A PET imageable marker for tumor angiogenesis could enable noninvasive monitoring of dynamic changes in patients, helping guide treatment strategies, optimal dose finding, and drug combination studies.

A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cell–Delivered TRAIL in Experimental Glioma Models
Tugba Bagci-Onder, Hiroaki Wakimoto, Maarten Anderegg, Cody Cameron, and Khalid Shah

Précis: Findings offer preclinical proof-of-concept for an effective combination of proapoptotic therapies that can eradicate malignant glioma cells in vitro and in vivo.

PDGFR Signaling Blockade in Marrow Stroma Impairs Lung Cancer Bone Metastasis
Raúl Catena, Diego Luis-Ravelo, Iker Antón, Carolina Zandueta, Pablo Salazar-Colocho, Leyre Larzábal, Alfonso Calvo, and Fernando Lecanda

Précis: Findings support the important concept that concomitant targeting of the tumor and tumor stroma can confer a far more effective approach to block bone metastasis in cancer.

TGF-βRI Kinase Inhibitor SD-208 Reduces the Development and Progression of Melanoma Bone Metastases
Khalid S. Mohammad, Delphine Javelaud, Pierrick G. J. Fournier, Maria Niewolna, C. Ryan McKenna, Xiang H. Peng, Vu Duong, Lauren K. Dunn, Alain Mauriel, and Theresa A. Guise

Précis: Preclinical proof-of-concept rationalizes application of small molecule inhibitors of TGF-β receptor signaling to prevent and treat osteolytic bone metastases in melanoma.

Autophagic Survival in Resistance to Histone Deacetylase Inhibitors: Novel Strategies to Treat Malignant Peripheral Nerve Sheath Tumors
Gonzalo Lopez, Keila Torres, Juehui Liu, Belinda Hernandez, Eric Young, Roman Belousoy, Svetlana Bolshakov, Alexander J. Lazar, John M. Slopis, Ian E. McCutcheon, David McConkey, and Dina Lev

Précis: Findings identify a potentially important resistance mechanism to histone deacetylase inhibitors, the abrogation of which could in particular enhance their anticancer activity against an aggressive neurological tumor that is poorly managed in the clinic.

Novel Synthetic Antagonists of Canonical Wnt Signaling Inhibit Colorectal Cancer Cell Growth
Jo Waaler, Ondrej Machon, Jens Peter von Kries, Steven Ray Wilson, Elsa Lundenes, Doris Wedlich, Dietmar Gradl, Jan Erik Paulsen, Olga Machonova, Jennifer L. Dembinski, Huyen Dinh, and Stefan Krauss

Précis: New small molecule inhibitors of the canonical Wnt pathway are described that potently block the growth of colorectal cancers.

Activation and Involvement of Ral GTPases in Colorectal Cancer
Timothy D. Martin, Jonathan C. Samuel, Elizabeth D. Routh, Channing J. Der, and Jen Jen Yeh

Précis: Findings validate the significance of a lesser studied Ras effector pathway for therapeutic inhibition of mutant KRAS in colorectal cancer.

Biological Activity of 4-Substituted Methoxybenzoyl-Aryl-Thiazole: An Active Microtubule Inhibitor
Chien-Ming Li, Zhao Wang, Yan Lu, Sunjoo Ahn, Ramesh Narayanan, Jeffrey D. Kearbey, Benno N. Parke, Wei Li, Duane D. Miller, and James T. Dalton

Précis: SMART compounds are as efficacious as currently approved antitubulin drugs for cancer treatment, but unlike these drugs they can circumvent P-glycoprotein–mediated drug resistance.

MiR-26a Inhibits Cell Growth and Tumorigenesis of Nasopharyngeal Carcinoma through Repression of EZH2
Juan Lu, Ming-Liang He, Lu Wang, Ying Chen, Xiaog Liu, Qi Dong, Yang-Chao Chen, Ying Peng, Kai-Tai Yao, Hsiang-Fu Kung, and Xiang-Ping Li

Précis: This study contributes significant new information concerning the molecular pathogenesis of nasopharyngeal carcinoma, a major cancer in China where it is associated with Epstein-Barr virus infection.
### TUMOR AND STEM CELL BIOLOGY

#### 234
**Phosphatase PRL-3 Is a Direct Regulatory Target of TGFβ in Colon Cancer Metastasis**
Yanjun Jiang, Xiao-Qiong Liu, Ashwani Rajput, Liying Geng, Melanie Ongchin, Qi Zeng, Gregory S. Taylor, and Jing Wang

**Précis:** Findings link TGFβ signaling in cancer progression to upregulation of a survival pathway that could be a determinant of metastasis, with implications for its therapeutic attack.

#### 245
**Snail2 is an Essential Mediator of Twist1-Induced Epithelial Mesenchymal Transition and Metastasis**
Esmeralda Casas, Jihoon Kim, Andrés Bendesky, Lucila Ohno-Machado, Cecily J. Wolfe, and Jing Yang

**Précis:** Findings identify an essential regulatory relationship between two key factors that control the EMT program to promote metastasis.

#### 255
**Higher miRNA Tolerance in Immortal Li-Fraumeni Fibroblasts with Abrogated Interferon Signaling Pathway**
Qunfang Li and Michael A. Tainsky

**Précis:** Results reveal the first solid evidence that disruption of IFN signaling is a checkpoint tolerizing cells to deregulation of miRNA expression, providing new insight into how certain transcription factors in innate immunity can promote cellular immortalization.

#### 266
**hTERT Overexpression Alleviates Intracellular ROS Production, Improves Mitochondrial Function, and Inhibits ROS-Mediated Apoptosis in Cancer Cells**
Inthirani R. Indran, Manoor P. Hande, and Shazib Pervaiz

**Précis:** Findings define a novel function for TERT in alleviating cellular ROS levels, endowing cancer cells with an additional mechanism to evade cell death stimuli.

#### 277
**Plasminogen Activator uPA is a Direct Transcriptional Target of the JAG1-Notch Receptor Signaling Pathway in Breast Cancer**
Mamiko Shimizu, Brenda Cohen, Pavel Goldvasser, Hal Berman, Carl Virtanen, and Michael Reedijk

**Précis:** Important new mechanistic findings link two pathways of poor prognosis in breast cancer.

### LETTER TO THE EDITOR

#### 287
**Fish Oil Exacerbates Colitis in SMAD3 Mice**
Lesley M. Butler and Mimi C. Yu

### CORRECTIONS

#### 289
**Correction: F3-Targeted Cisplatin-Hydrogel Nanoparticles as an Effective Therapeutic that Targets Both Murine and Human Ovarian Tumor Endothelial Cells In vivo**

#### 290
**Correction: Induction of Human Epithelial Stem/Progenitor Expansion by FOXM1**

### ABOUT THE COVER

Double immunofluorescence for nestin (pink) and the endothelial marker CD34 (green) with EGFR fluorescence in situ hybridization (red) confirms expression of nestin in endothelial cells and in GBM cells of patients treated with cediranib. For details, see the article by di Tomaso et al. on page 19 of this issue.